The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Examination of resistance to nivolumab monotherapy through single-cell analysis of tumors from patients enrolled in the HCRN GU16-260 study of nivolumab monotherapy.
 
David A. Braun
Honoraria - LM Education/Exchange Service
Consulting or Advisory Role - Abbvie; Adept Field Solutions; Aptitude Health; AVEO; Blueprint Partnership; Bristol-Myers Squibb; Catenion; Cello Health; Charles River Associates; Dedham Group; Defined Health; Exelixis; Insight Strategy; Octane Co.; Schlesinger Associates; Slingshot Insights; Trinity Group
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Kelly Street
No Relationships to Disclose
 
Opeyemi Jegede
Research Funding - Bristol Myers Squibb Foundation
 
Neil Ruthen
No Relationships to Disclose
 
Miya Hugaboom
No Relationships to Disclose
 
Nicholas R Schindler
No Relationships to Disclose
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; AVEO; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer; Synthekine; Werewolf Therapeutics
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca; AVEO; Bristol-Myers Squibb/Medarex; Calithera Biosciences; EMD Serono; Exelixis; IMV; Janssen; Janssen; MEI Pharma; Merck; Pfizer; Regeneron; Seattle Genetics/Astellas; Signatera
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst)
 
Jeffrey A. Sosman
Honoraria - Apexigen; Aveo; Iovance Biotherapeutics; Jazz Pharmaceuticals
Consulting or Advisory Role - Apexigen; Iovance Biotherapeutics; Jazz Pharmaceuticals
 
Naomi B. Haas
Consulting or Advisory Role - AVEO; Calithera Biosciences; Eisai; Exelixis; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Expert Testimony - Lilly (I)
 
Michael E. Hurwitz
Employment - Arvinas (I); Gamida Cell (I); Pfizer (I)
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; crispr therapeutics; Exelixis; Janssen; Nektar
Research Funding - Achilles Therapeutics; Apexigen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Endocyte; Endocyte; Genentech; Genmab; Innocrin Pharma; Iovance Biotherapeutics; Lilly; Merck; Nektar; Novartis; Novartis; Pfizer; Progenics; Sanofi/Aventis; Seagen; Torque; Unum Therapeutics
 
Hans J. Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology
Research Funding - aravive (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer
 
Sabina Signoretti
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; crispr therapeutics; Merck
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Receives royalties from Biogenex
Other Relationship - AACR; NCI
 
Michael B. Atkins
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - Adagene; Agenus; Asher Biotherapeutics; AstraZeneca; Aveo; Bristol-Myers Squibb; Calithera Biosciences; Cota Healthcare; Eisai; Ellipses Pharma; Exelixis; Fathom Biotechnology; Genentech; GlaxoSmithKline; Idera; Iovance Biotherapeutics; Leads Biolabs; Merck; Novartis; Oncorena; PACT Pharma; Pfizer; Pneuma Respiratory; Pyxis; Sanofi; Scholar Rock; Seagen; Simcha Therapeutics; Surface Oncology; Takeda; Werewolf Pharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Catherine J. Wu
Stock and Other Ownership Interests - Biontech; Biontech (I)
Research Funding - Pharmacyclics/Janssen